Our top pick for
Building a portfolio
Core Laboratories N.V is an oil & gas equipment & services business based in the US. Core Laboratories N-V shares (CLB) are listed on the NYSE and all prices are listed in US Dollars. Core Laboratories N-V employs 3,700 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$8.82 - $41.99|
|50-day moving average||$35.69|
|200-day moving average||$25.44|
|Wall St. target price||$29.58|
|Dividend yield||$0.28 (0.81%)|
|Earnings per share (TTM)||$2.25|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Core Laboratories N-V stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Core Laboratories N-V's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Core Laboratories N-V's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Core Laboratories N-V shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Core Laboratories N-V's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.4543. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Core Laboratories N-V's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Core Laboratories N-V's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $70.5 million.
The EBITDA is a measure of a Core Laboratories N-V's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$487.3 million|
|Operating margin TTM||10.19%|
|Gross profit TTM||$102.1 million|
|Return on assets TTM||4.62%|
|Return on equity TTM||-75.33%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 4.3 million Core Laboratories N-V shares held short by investors – that's known as Core Laboratories N-V's "short interest". This figure is 14.5% down from 5.1 million last month.
There are a few different ways that this level of interest in shorting Core Laboratories N-V shares can be evaluated.
Core Laboratories N-V's "short interest ratio" (SIR) is the quantity of Core Laboratories N-V shares currently shorted divided by the average quantity of Core Laboratories N-V shares traded daily (recently around 450030.76923077). Core Laboratories N-V's SIR currently stands at 9.62. In other words for every 100,000 Core Laboratories N-V shares traded daily on the market, roughly 9620 shares are currently held short.
However Core Laboratories N-V's short interest can also be evaluated against the total number of Core Laboratories N-V shares, or, against the total number of tradable Core Laboratories N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Core Laboratories N-V's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Core Laboratories N-V shares in existence, roughly 100 shares are currently held short) or 0.1101% of the tradable shares (for every 100,000 tradable Core Laboratories N-V shares, roughly 110 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Core Laboratories N-V.
Find out more about how you can short Core Laboratories N-V stock.
Dividend payout ratio: 5.06% of net profits
Recently Core Laboratories N-V has paid out, on average, around 5.06% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Core Laboratories N-V shareholders could enjoy a 0.12% return on their shares, in the form of dividend payments. In Core Laboratories N-V's case, that would currently equate to about $0.28 per share.
While Core Laboratories N-V's payout ratio might seem low, this can signify that Core Laboratories N-V is investing more in its future growth.
Core Laboratories N-V's most recent dividend payout was on 15 February 2021. The latest dividend was paid out to all shareholders who bought their shares by 21 January 2021 (the "ex-dividend date").
Core Laboratories N-V's shares were split on a 2:1 basis on 8 July 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Core Laboratories N-V shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Core Laboratories N-V shares which in turn could have impacted Core Laboratories N-V's share price.
Over the last 12 months, Core Laboratories N-V's shares have ranged in value from as little as $8.8175 up to $41.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Core Laboratories N-V's is 3.4057. This would suggest that Core Laboratories N-V's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Core Laboratories N. V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and petroleum products; and proprietary and joint industry studies. The Production Enhancement segment offers services and products relating to reservoir well completions, perforations, stimulations, and production.
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.